Teva Wants In On FDA Suit To Defend Dibs On Xifaxan Generic
Teva Pharmaceuticals should be allowed to protect its generic exclusivity for its version of a Bausch Health unit's blockbuster irritable bowel syndrome treatment, Xifaxan, by intervening in a competitor's suit, the...To view the full article, register now.
Already a subscriber? Click here to view full article